Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
Inv. presentation
Director departure
NovaBay Pharmaceuticals, Inc. (NBY) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2019 GN NovaBay Pharmaceuticals Announces Pricing of $2.7 Million Private Placement of Preferred Stock and Accompanying Warrants to Purchase Common Stock
08/09/2019 GN NovaBay Pharmaceuticals Announces Pricing of $4.2 Million Registered Direct Offering
09/26/2012 GN NovaBay Pharmaceuticals (NBY) Receives $2.6 Million From Partner Galderma
09/24/2012 GN Galderma and NovaBay Enroll First Patients in Phase 2b Clinical Study of NVC-422 for Impetigo
09/14/2012 GN NovaBay Pharmaceuticals (NBY) Announces Expansion of Strategic Marketing Agreement for NeutroPhase(R) in Southeast Asia
09/12/2012 GN NovaBay Pharmaceuticals Co-Authors Novel Study Demonstrating Chemical Impact of N-Chlorotaurine and NVC-422 on Bacterial Toxins
09/04/2012 GN NovaBay Pharmaceuticals to Present at Rodman ' Renshaw 14th Annual Healthcare Conference
08/27/2012 GN NovaBay Pharmaceuticals Receives Additional FDA 510(k) Clearance for NeutroPhase(R) Wound Cleanser
08/20/2012 GN NovaBay Pharmaceuticals to Present at Southern California Investor Conference
08/09/2012 GN NovaBay Pharmaceuticals Provides Second Quarter 2012 Financial Results
07/05/2012 GN NovaBay Pharmaceuticals to Present at JMP Securities Healthcare Conference
06/06/2012 GN NovaBay Announces Successful End-of-Phase 2a FDA Meeting for Dermatology Program
05/31/2012 GN NovaBay Pharmaceuticals Strengthens Global Aganocide(R) Patent Estate With Seven New Patents
05/03/2012 GN NovaBay Pharmaceuticals Provides Q1 - 2012 Financial Results
04/19/2012 GN NovaBay's NeutroPhase(R) Supports Healing of Chronic Wounds
03/06/2012 GN NovaBay Pharmaceuticals to Present at Two Upcoming Investor Conferences in March
02/07/2012 GN NovaBay Pharmaceuticals to Hold Conference Call to Provide Year-End Business Update and 2012 Outlook
01/09/2012 GN NovaBay Pharmaceuticals Announces Strategic Marketing Agreement for NeutroPhase in China
11/30/2011 GN NovaBay Establishes Primary Proof of Concept for NVC-422 Phase 2 UCBE Clinical Program
11/07/2011 GN NovaBay Pharmaceuticals Reports Third Quarter Financial Results
10/14/2011 GN NovaBay Pharmaceuticals Spotlights NeutroPhase(R) at the Symposium on Advanced Wound Care (SAWC)
10/04/2011 GN NovaBay Pharmaceuticals Names David W. Stroman, Ph.D. as Head of Ophthalmic Drug Development
09/28/2011 GN NovaBay Pharmaceuticals Names Russell A. Hoon as Vice President of Its Advanced Wound Care Business Unit
09/12/2011 GN NovaBay Pharmaceuticals' Reports Positive Results in Sinus Infection Study
08/25/2011 GN NovaBay Pharmaceuticals Highlighted in Cataract ' Refractive Surgery Today
08/24/2011 GN NovaBay Pharmaceuticals to Present at The 2011 Southern California Investor Conference
08/10/2011 GN NovaBay Pharmaceuticals Reports Second Quarter Financial Results
07/11/2011 GN NovaBay Pharmaceuticals Provides Business Update
07/05/2011 GN NovaBay Pharmaceuticals Announces the Closing of Its $5.2 Million Registered Direct Offering of Common Stock and Warrants
06/29/2011 GN NovaBay Pharmaceuticals, Inc. Announces Pricing of a $5.2 Million Registered Direct Offering of Common Stock and Warrants
05/23/2011 GN NovaBay Pharmaceuticals to Present at the 7th Annual Spring Growth Stock Conference Hosted by Security Research Associates, Inc. on May 24
05/18/2011 GN NovaBay Pharmaceuticals Reports Results from Phase 2 Clinical Trial of NVC-422 for Adenoviral Conjunctivitis
05/17/2011 GN NovaBay Pharmaceuticals to Announce Results of Phase 2 Clinical Trial for Treatment of Adenoviral Conjunctivitis
05/16/2011 GN NovaBay Pharmaceuticals, Inc. Reports First Quarter Financial Results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy